Crosslinking of alpha 2-antiplasmin to fibrin
- PMID: 11460490
- DOI: 10.1111/j.1749-6632.2001.tb03520.x
Crosslinking of alpha 2-antiplasmin to fibrin
Abstract
Human alpha 2-antiplasmin (alpha 2AP) is the primary inhibitor of plasmin-mediated fibrinolysis and is an efficient substrate of activated factor XIII (FXIIIa). Among 452 amino acid residues in alpha 2AP, Gln2 is believed to be the sole FXIIIa-reactive site that participates in crosslinking alpha 2AP to fibrin. We studied the effect of mutating Gln2 on the ability of FXIIIa to catalyze crosslinking of alpha 2AP to fibrin. By FXIIIa catalysis, [14C]methylamine was incorporated into a Q2A-alpha 2AP mutant in which Gln2 (Q) was replaced by Ala (A), thereby indicating that wildtype alpha 2AP has more than one FXIIIa-reactive site. To identify the FXIIIa-reactive sites in alpha 2AP, wildtype alpha 2AP and Q2A-alpha 2AP were labeled with 5-(biotinamido)pentylamine by FXIIIa. Each labeled alpha 2AP was digested with trypsin and applied to an avidin affinity column to capture labeled peptides. Edman sequencing and mass analysis of each labeled peptide showed that out of 35 Gln residues in wildtype alpha 2AP, four were labeled with the following order of efficiency: Gln2 > Gln21 > Gln419 > Gln447. Q2A-alpha 2AP was also labeled at the three minor sites, Gln21 > Gln419 > Gln447. Q2A-alpha 2AP became crosslinked to fibirin(ogen) by FXIIIa catalysis at approximately one-tenth the rate of wt-alpha 2AP. These results demonstrate that alpha 2AP has one primary (Gln2) and three minor substrate sites for FXIIIa and that the three minor sites identified in this study can also participate in crosslink formation between alpha 2AP and fibrin, but at a much lower efficiency than the Gln2 site.
Similar articles
-
Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase.J Biol Chem. 2000 Dec 1;275(48):37382-9. doi: 10.1074/jbc.M003375200. J Biol Chem. 2000. PMID: 10958788
-
Why alpha-antiplasmin must be converted to a derivative form for optimal function.J Thromb Haemost. 2007 Oct;5(10):2095-104. doi: 10.1111/j.1538-7836.2007.02707.x. J Thromb Haemost. 2007. PMID: 17883704
-
Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant.Blood. 1999 Jul 1;94(1):164-71. Blood. 1999. PMID: 10381509
-
Determinants of substrate specificity for factor XIII.Semin Thromb Hemost. 1996;22(5):369-76. doi: 10.1055/s-2007-999034. Semin Thromb Hemost. 1996. PMID: 8989819 Review.
-
[Analysis of alpha 2-plasmin inhibitor].Rinsho Byori. 1985 Feb;Spec No 61:97-105. Rinsho Byori. 1985. PMID: 2860263 Review. Japanese. No abstract available.
Cited by
-
Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.Int J Mol Sci. 2021 Mar 17;22(6):3055. doi: 10.3390/ijms22063055. Int J Mol Sci. 2021. PMID: 33802692 Free PMC article. Review.
-
Molecular Detection of Venous Thrombosis in Mouse Models Using SPECT/CT.Biomolecules. 2022 Jun 13;12(6):829. doi: 10.3390/biom12060829. Biomolecules. 2022. PMID: 35740954 Free PMC article.
-
Association of Genetic Polymorphisms of Fibrinogen, Factor XIII A-Subunit and α2-Antiplasmin with Fibrinogen Levels in Pregnant Women.Life (Basel). 2021 Dec 3;11(12):1340. doi: 10.3390/life11121340. Life (Basel). 2021. PMID: 34947871 Free PMC article.
-
Reactivity of the N-terminal region of fibronectin protein to transglutaminase 2 and factor XIIIA.J Biol Chem. 2011 Sep 16;286(37):32220-30. doi: 10.1074/jbc.M111.255562. Epub 2011 Jul 11. J Biol Chem. 2011. PMID: 21757696 Free PMC article.
-
Detection of factor XIII inhibitors in 33 patients with autoimmune factor XIII deficiency in Japan.Int J Hematol. 2024 Oct;120(4):472-481. doi: 10.1007/s12185-024-03807-y. Epub 2024 Jun 19. Int J Hematol. 2024. PMID: 38896335
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources